Novo Nordisk A/S: Key Facts
- FY2025 revenue: DKK 309.064B (about $46.0B).
- FY2025 net income: DKK 102.434B (about $15.2B).
- Employees: 69,505 employees as of December 31, 2025.
- Leadership: CEO Maziar "Mike" Doustdar.
- Status: public, NYSE: NVO.
- Headquarters: Bagsvaerd, Denmark.
How Novo Nordisk Makes Money
Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Why Novo Nordisk Matters
Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Biggest Risk
The biggest risk is GLP-1 competition, pricing pressure, supply execution, side-effect scrutiny, and dependence on diabetes and obesity growth.
